Teva’s three 40mg Copaxone patents in the Orange Book (8232250, 8399413, 8969302) are method-of-use patents, which are generally easier to invalidate than composition-of-matter patents.
Yesterday’s USPTO news (#msg-116493514) concerns the first two of the three aforementioned patents, and a USPTO preliminary ruling on an IPR for the third patent is expected soon.
Market Data 
Markets 
AI
